Lydia S.
- Country
- Italy
- Department
- Oncology
Research Overview
- Phase 3 Study of BGB-11417 plus Zanubrutinib versus Venetoclax plus Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia
- Phase 3 Multicenter Randomized Study of Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated Symptomatic Splenic Marginal Zone Lymphoma
- Phase 2 Randomized Multicenter Trial of Vemurafenib and Rituximab Versus Cladribine in Treatment-Naïve Hairy Cell Leukemia Patients
Data & Insights
Has run more than one trial at 13 of 84 partner sites.
Specializations
Hematologic Malignancies
This investigator specializes in treating rare blood cancers, with particular focus on splenic marginal zone lymphoma (SMZL) and hairy cell leukemia (HCL).
- Novel Treatment Approaches
- Chemotherapy-Free Alternatives
- Targeted Therapies
Expertise includes evaluating innovative treatment combinations involving rituximab, zanubrutinib, and vemurafenib for blood disorders.
Lymphoma Treatment
Focused on developing treatment strategies for marginal zone lymphomas, particularly exploring combination therapies to improve patient outcomes.
- Treatment-Naive Patients
- Progression-Free Survival
- Monotherapy Approaches
Special interest in comparing therapeutic efficacy between combination treatments and standard monotherapy regimens.
Leukemia Management
Dedicated to advancing treatment options for hairy cell leukemia, investigating alternatives to conventional chemotherapy approaches.
- First-Line Treatments
- Minimal Residual Disease
- Treatment Toxicity Reduction
Expertise in evaluating therapeutic strategies that minimize toxicity while maintaining treatment effectiveness.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.